III期非小细胞肺癌心脏放疗剂量与纵隔淋巴结受累的关系
本研究回顾性分析56例2007至2014年接受根治性放疗的III期非小细胞肺癌患者,由单一医生按RTOG 1106图谱重新勾画心脏,评估心脏剂量与纵隔淋巴结站受累的关系。结果显示多站及第7站淋巴结受累患者平均心脏剂量显著更高,第7站受累与所有心脏参数显著相关(P < .001)。结论提示心脏剂量可能反映其他预后因素而非独立预测因子。
要点
- 多站及第7站纵隔淋巴结受累者平均心脏剂量显著更高。
- 第7站淋巴结受累与所有检测的心脏剂量参数显著相关(P < .001)。
- 心脏剂量可能为III期NSCLC其他预后因素的替代指标。
核心结论
- 心脏剂量可能是III期非小细胞肺癌其他预后因素的替代指标,而非结局的独立预测因子。
研究设计与样本
- 回顾性研究纳入2007至2014年接受根治性放疗的56例III期非小细胞肺癌患者,由单一医生按RTOG 1106图谱重新勾画心脏。
主要发现
- 多站淋巴结受累和第7站受累患者的平均心脏剂量显著更高。
- Spearman秩相关显示第7站受累与所有检测的心脏参数显著相关(P < .001)。
- 受累淋巴结站数≥2的患者所有检测心脏参数剂量均显著高于仅1站或无淋巴结受累者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The results from Radiation Therapy Oncology Group (RTOG) 0617, a dose escalation trial that compared treatment with 60 Gy versus 74 Gy for patients with stage III non-small cell lung cancer (NSCLC), suggested that in these patients, the heart dose from radiation therapy correlates with survival. In particular, the study noted that patients with a high heart V5 and V30 had a poorer overall survival; however, the exact cause of this correlation is not known. We hypothesize that heart dose may be a surrogate for mediastinal nodal involvement, which has prognostic value in NSCLC. This study evaluates the relationship between heart dose and involvement of mediastinal lymph nodes in patients with stage III NSCLC treated with radiation therapy. METHODS AND MATERIALS: A total of 56 patients were identified and treated with definitive radiation therapy from 2007 to 2014. The heart was recontoured for every patient by a single physician, per the RTOG 1106 contouring atlas. We assessed lymph node station involvement using pretreatment data, and nodal coverage was confirmed on plan review. RESULTS: Mean heart dose was found to be significantly higher in patients with multinodal station and level 7 involvement. On Spearman's rank correlation, level 7 was significantly associated with all heart parameters tested (P < .001). Patients who had 2 or more lymph node stations involved were found to have significantly higher heart doses for all parameters tested when compared with those who had only one station involved or no nodal involvement. CONCLUSIONS: Our findings suggest that heart dose may be a surrogate for other prognostic factors in stage III NSCLC rather than an independent predictor of outcome.
引用
- McNew LK, Bowen SR, Gopan O, et al. The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients. Adv Radiat Oncol. 2017. PMID: 28740931. doi:10.1016/j.adro.2017.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。